Abstract 428P
Background
Bone marrow aspiration although being a common procedure is associated with significant pain and its reduction remains an unmet need. We evaluated the use of tramadol and eutectic mixture of local anaesthetics (prilocaine plus lignocaine) (EMLA) for reducing the severity of pain.
Methods
In this pilot study, we compared the addition of either Tramadol 50 mg per oral (Arm T) or EMLA local application (Arm E) or no added intervention (Arm L) in addition to local infiltration with lignocaine 2% before bone marrow aspiration in adults suspected / confirmed with malignancy. Both, tramadol and EMLA were administered one hour prior to the procedure. Primary end point was reduction in pain intensity with these interventions compared to local infiltration alone. Pain was assessed using numerical FACES pain scale ( 0-10), a visual analogue scale.Secondary end points were to see the effect on pre procedure apprehension and to find out other factors associated with increased pain associated with the procedure.
Results
A total of 225 patients were included in the study, 75 each in tramadol(T), EMLA(E) and only lignocaine local infiltration(L) arms respectively. The mean pain intensity on the visual scale was significantly lower in tramadol arm ( T,E,L - 3.3 , 4.5 , 4.7 respeactively)(p < 0.05). There was significant reduction in percentage of patients who experienced moderate / severe pain (4 or more) in tramadol arm (T,E,L - 47%,76%,84% respectively)(p < 0.05). Duration of procedure > 10 minutes and age > 50 were positively correlated with more pain. Leukemia patients had significantly more pain compared to lymphoma and other solid malignancies. Only 4 patients had sedation/dizziness in tramadol arm compared to 2 each in the other two arms. No significant effect on pre procedure apprehension was noted in any of the arms.
Conclusions
Tramadol appears to have a preventive effect on bone marrow aspiration associated pain and appears to be well tolerated. Whereas EMLA was not associated with such effect. Larger studies may be done to ascertain the same.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of medical oncology, Kidwai cancer institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract